Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 189 Neoplasm Metastasis 24 Neoplasms 23 Ovarian Neoplasms 12 Sarcoma 10 Pancreatic Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 8 Melanoma 7 Endometrial Neoplasms 7 Colorectal Neoplasms 7 Carcinoma, Non-Small-Cell Lung 7 Prostatic Neoplasms 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Multiple Myeloma 6 Lymphoma, Non-Hodgkin 6 Head and Neck Neoplasms 6 Carcinoma, Renal Cell 6 Breast Diseases 6 Recurrence 5 Medulloblastoma 5 Lung Neoplasms 5 Leukemia, Myeloid, Acute 5 Triple Negative Breast Neoplasms 4 Sarcoma, Ewing 4 Neoplasms by Site 4 Lymphoma, Mantle-Cell 4 Liposarcoma 4 Glioma 4 Glioblastoma 4 Colonic Neoplasms 4

Interventions

Letrozole 2 ribociclib 1 palbociclib 1 abemaciclib 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Fulvestrant 1 Epirubicin 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × palbociclib × Clear all

NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡